Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Metalsource Mining Extends Strike Length of Mineralization at Silver Hill with 65m South Step Out from SH26-19
